No hormone therapy | Hormone therapy | p-value | |
Patients | 116 014 | 23 469 | |
Age, years | 53.0±5.2 | 53.0±5.2 | 1.00 |
Age groups, years | 1.00 | ||
45–49 | 31 703 (27.3) | 6387 (27.2) | |
50–54 | 39 673 (34.2) | 8054 (34.3) | |
55–59 | 24 649 (21.2) | 4946 (21.1) | |
60–64 | 19 989 (17.2) | 4082 (17.4) | |
Years of asthma | 7.7±5.9 | 7.4±5.8 | <0.001 |
Household income levels | 1.00 | ||
Lowest | 7 (0.0) | 20 (0.1) | |
Second lowest | 4711 (4.1) | 1013 (4.3) | |
Second highest | 37 355 (32.2) | 7558 (32.2) | |
Highest | 73 941 (63.7) | 14 878 (63.4) | |
Level of education | 1.00 | ||
Long-cycle higher education | 6818 (5.9) | 1419 (6.0) | |
Medium-cycle higher education or bachelor's degree | 30 893 (26.6) | 6245 (26.6) | |
Upper or lower secondary school | 36 696 (31.6) | 7387 (31.5) | |
Vocational upper secondary school | 41 607 (35.9) | 8418 (35.9) | |
Inhaled anti-asthma medication | |||
Inhaled corticosteroids | 74 681 (64.4) | 15 800 (67.3) | <0.001 |
Mean±sem dose, µg | 406±5 | 421±5 | 0.002 |
Long-acting β2-agonists | |||
Formoterol | 23 014 (19.8) | 5142 (21.9) | <0.001 |
Salmeterol | 14 622 (12.6) | 3580 (15.3) | <0.001 |
Indacaterol | 326 (0.3) | 106 (0.5) | <0.001 |
Vilanterol | 232 (0.2) | 68 (0.3) | <0.001 |
Short-acting β2-agonists | |||
Terbutaline | 45 854 (39.5) | 9526 (40.6) | <0.001 |
Salbutamol | 22 035 (19.0) | 4908 (20.9) | <0.001 |
Data are presented as n, mean±sd or n (%), unless otherwise stated.